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Background: The fixed, progressive disability associated with late Multiple Sclerosis (MS) is
known to have a major impact on patients and their families, but the impact of relapse earlier
in the disease course is less well documented, particularly from the patient's perspective. This
study aimed to understand the effects of relapse for people with MS (PwMS), focussing on the
years immediately after starting disease modifying therapy (DMT) when experience of a relapse
may particularly influence a patient's opinions of their disease and its therapy.
Methods: This was a multi-centre, retrospective, observational research study, recruiting
patients from 7 UK NHS Hospital Trusts. Consenting patients with relapsing-remitting MS
(RRMS), who had started a DMT more than 36 months before screening, were sent a study
questionnaire. Data on MS relapses and treatments over 3 years were collected simultaneously
from medical records.
Results: One hundred and three patients completed the questionnaires. Relapses were under-
reported to health care professionals, with 28% of respondents failing to report their most recent
attack and 46% declaring they had failed to report an attack in the past. During their most recent
relapse, 67% of those in paid employment reported taking time off sick, 48% reduced working
hours temporarily, and 41% worked reduced hours and took time off sick. Sixty-six percent
required additional support to undertake routine daily tasks during their most recent relapse.
A range of effects of relapse which cannot be measured in financial terms were also reported,
including effects on physical abilities, mental health and family roles and relationships.
Conclusion: This contemporary UK-based study provides an insight into the experience of relapse
early in the treatment of RRMS from the patient perspective. The comparison of documented14.02.006
hed by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/3.0/).
28401720.
sociates.com (F. Percival).
451The UK patient experience of relapse in multiple sclerosispatient reported relapses reveals some deficiencies in the recording of relapses which is important
to address in view of the reported impact of individual relapses, and emphasises relapse reduction
as a worthy treatment aim.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multiple Sclerosis (MS), with an onset typically between the
ages of 20 and 40, has a major impact on the physical
wellbeing and social role not only of the person directly
affected, but also of their relatives. The cost of late
disability is the main driver in economic impact models
(Hakim et al., 2000). A UK cost-of-illness analysis showed
that employment rates reduce from 82% in early disease to
6% at an Expanded Disability Status Scale (EDSS) score of 7
(Kobelt et al., 2006).
However, a focus on the health economics of progressive
disease may underestimate the impact of relapse on patients,
carers and healthcare providers. Some effects, such as the
strong emotional reactions elicited in patients and loved ones
(Kalb, 2007), may not routinely be measured. In clinical trials of
existing DMTs, reduction in disability appears to be driven by
reduction in the clinical relapse rate. The occurrence of relapse
remains the principal determinant for starting or escalating
Disease Modifying Therapies (DMTs) under current UK DMT
guidance (Association of British Neurologists, 2001; National
Institute for health and Care Excellence, 2007, 2012).
This report describes the impact of relapse in a cohort of
patients recruited to study the experience of the first
3 years of de novo DMT treatment. We focus here on the
wider burden of relapse, including the change in patient
contact with health care professionals, the financial impact
of a relapse on People with Multiple Sclerosis (PwMS) and
the impact of a relapse on patients' attitudes to DMT.
Discrepancies between clinician-documented and patient-
reported relapse symptoms were also explored.
2. Methods
This was a multi-centre, retrospective survey of patients
recruited from 7 UK NHS Hospital Trusts, selected to give a
geographical spread across England and Wales. The study
received a favourable ethical opinion from the London-
Bromley Research Ethics Committee (ref. 12/LO/0248).
2.1. Study subjects
Data were obtained from participant self-completed question-
naires. Demographic details and information on relapses
reported to the clinician within the first 3 years following
DMT initiation were obtained from hospital medical records
and, where possible, compared with patient-reported details.
Inclusion criteria were: (1) RRMS diagnosis by 2005 MacDonald
criteria (Polman et al., 2005); (2) first DMT after 1st July 2007
and at least 36 months before screening inclusion date;
(3) ability to complete study questionnaires (by carer or self);and (4) consent to complete study questionnaires and for a
researcher to review medical records.
To characterise the cohort, patients were also asked to
complete an EQ5D, Beck's Depression Inventory scale and
the Patient Determined Disease Steps score (PDDS)
(Learmonth et al., 2013).
Written consent was sought from eligible patients by post
by their clinician. Patients were approached in consecutive
date order of DMT initiation, until all eligible or 40 study
participants per site had been recruited.2.2. Data collection, quality control and analysis.
Patient questionnaires were completed between July 2012
and March 2013. Some patients did not fully complete the
questionnaire, therefore the number of respondents (n)
varied by question. Where self-evident from subsequent
answers, blank yes/no questions were completed by an
investigator.
Relapse symptoms were grouped into domains to compare
clinician and patient reports. In clinician notes, relapse
severity was defined as: Severe: if documented as ‘severe’ or ‘disabling’,
required hospitalisation or steroid therapy. Moderate: if neither criteria for ‘severe’ nor ‘mild’ were
applicable. Mild: if documented as ‘mild’ or equivalent.The term ‘relapse’ was defined for patients in the ques-
tionnaire as: either the appearance of new symptoms related
to MS or very definite worsening of old symptoms, which
lasted for at least 24 h and occurred after the patient had
been stable for at least a month (with the absence of raised
temperature, infection, or any other health problem).
Patients were asked to comment in detail on their most
recent relapse. For some patients (n=27), the relapse
described was outside the 3-year period following drug
initiation, so for these patients no comparison with a
relapse documented in the medical record was possible.
Patients were also asked to record details of all MS-related
visits they made to Health Care Professionals (HCPs) during
their most recent relapse.
Responses to questions with multiple-choice options were
analysed quantitatively and summarised as percentages.
The responses to the open ‘comments’ question were analysed
qualitatively, by thematic analysis. This was conducted by two
researchers separately, with a third researcher arbitrating
between any differences in the themes identified.
M. Duddy et al.4523. Results
3.1. Study sample: patients, disease and
treatment history
One hundred and forty one (37%) of the 378 MS patients
identified as eligible consented to take part in the study and
103 (73% of those who consented or 27% of those eligible)
returned questionnaires (‘the respondents’) although not all
answered every question; number of respondents is
reported with each result. In one case, due to a move to
another area, hospital notes for the study period were
incomplete, reducing the analysable cohort to 102 where
medical record data was needed. Mean (SD) age was 40.2
(10.1) years at DMT initiation and 44.9 (10.0) years at
questionnaire completion. Seventy seven percent of parti-
cipants were female, (n=79/103). Fifty nine percent of the
study sample (n=58/98 evaluable patients) started DMTs
within 1 year of RRMS diagnosis with a median time from MS
diagnosis to first DMT of 34 weeks (Interquartile range (IQR)
15 to 84).
There was a wide range of MS severity as described by
PDDS, with 32% of 100 respondents reporting only mild
impairment or normal functioning and 10% requiring bilat-
eral support/a wheelchair or buggy/bedridden. Median
PDDS score was 3, indicating gait disability (IQR 1 to 4),
which equates approximately to EDSS (Kurtzke, 1983)
grades 4–5.5.
Quality of life (EQ5D) mean score was 0.60 (SD 0.21) and
EQ5D VAS mean score was 63 (SD 22) (Szende and Williams,
2004). Forty-one percent of patients had a Beck's Depression
Inventory (BDI) score Z19, indicating moderate or severe
depression, with a median score of 15 (IQR 9 to 23).
During the 3 years following first DMT initiation, 59% (60/
102) of patients experienced at least one relapse. The
median number of documented relapses per patient was 1
(range 0–6). The mean annualised relapse rate (ARR) was
0.36 (n=102), with 63%, 49% and 41% of patients remaining
relapse-free for 1, 2 and 3 years respectively. The 60
patients who relapsed during the first 3 years had a total
of 109 relapses recorded in the medical record. Of these, 27
(25%) were mild, 42 (39%) moderate, 39 (36%) severe and 1
(1%) not known. 30/102 (29%) patients experienced at least
one severe relapse.
Interferon was the initial DMT for 82/102 (80%) patients,
with 58 (57%) receiving interferon as their only treatment.
Other first line DMTs were glatiramer acetate for 19 (19%)
patients and natalizumab for 1 patient.
Fifty nine (58%) patients remained on their initial DMT for
at least 3 years, 39 (38%) changed drug at least once, with
8 of these patients subsequently discontinuing all DMTs, and
4 (4%) discontinuing treatment after only one DMT.
3.2. Data from patient-completed questionnaire
3.2.1. Reporting of relapses
Twenty nine (28%) of 102 patients responded that they did
not report their most recent relapse to the MS specialist
team. The most common reasons recorded were ‘mild
relapse/not necessary’ (n=5) and 'made contact with GP'
(n=4).Forty-six (46%) of 101 respondents reported that they had
experienced a relapse in the past but not contacted a
healthcare professional. The main reasons were: ‘consid-
ered symptoms too mild’ (18 patients) and ‘did not feel
there was anything staff could do’ (8 patients).
In 40/103 (39%) instances the most recent relapse
described by the patient in their questionnaire response
fell within the retrospective data collection period and was
confirmed by the patient as having been reported to a
clinician. When the information provided in the question-
naires was compared with the data from the retrospective
review of the medical records, in 27/40 (68%) instances the
relapse described by the patient could be identified. Exact
concordance between the symptoms reported by the
patient and the medical record was found in 10/27 (37%)
relapses. More symptoms were reported by patients than
clinicians in 11/27 (41%) relapses and in 5/27 (19%) more
symptoms were recorded by clinicians than reported by
patients (for one patient the same number but different
symptoms were recorded). Four episodes reported by the
patients as relapses were not felt to be relapses in the
opinion of the clinician, with valid reasons recorded.
The most frequently reported of 10 symptom domains
was lower limb weakness/clumsiness/sensory disturbance/
mobility; this was recorded by the clinician in 74% of
relapses and by the patient in 89%.3.2.2. Impact of most recent relapse on work and daily
living
Of the 101 patients who responded to this question, 67
(66%) reported being in paid employment before their most
recent relapse. During the relapse 44/66 (67%) reported
taking time off sick, 32 (48%) reduced working hours
temporarily, and 27 (41%) reported both working reduced
hours and taking time off sick. A permanent change to their
working pattern was reported by 11/62 (18%) patients, with
6/62 (10%) giving up work entirely.
Sixty seven (66%) of 102 patients required additional
support to undertake routine daily tasks during their most
recent relapse. Fifty two (78%) of these reported receiving
help from family and friends and 10 (15%) reported incurring
costs because of the need for additional help or support.3.2.3. Financial impact of most recent relapse
Relapses also had a financial impact for some patients; 31%
reported a reduction in family income. Where a value was
reported (n=22), the reduction per month ranged from
£100 to £1000. A change in benefit payments was reported
by 7 patients. Where a value was reported, the mean
increase was £303 (range, £40 to +£600) per month
(Table 1).
Twenty patients who recorded both a decrease in income
and details of whether there had been a change in their
benefits, had a mean (SD) monthly reduction in income of
£434.00 (£378.53).
Additional one-off costs were reported by 10 patients and
these varied; e.g. purchase of a stair lift (1 patient £6000),
wheelchair hire (1 patient £60). Twenty five patients
reported incurring healthcare attendance associated park-
ing costs, 44 patients incurred additional fuel costs and 13
patients incurred public transport costs.
Table 2 Themes in open comments from questionnaire
respondents.
Theme Sub-themes
Impact on health and
ability
Physical effects
Effect on abilities
Psychological effects
Burden on family/
friends
Need to take over practical tasks
Emotional burden
Working life Negative impact of relapse
Attitude of employers
Finances Association with impact on work
Mitigating circumstances reducing
the impact
Factors affecting
relapse
Triggers of relapse
Factors affecting an existing
relapse
Health care provision Positive comments
Inadequate provision
Treatment effects Positive effects
Negative effects
Control Loss of control over aspects of life
Regaining control
Coping Strategies
Mitigating circumstances
Table 1 Financial costs incurred during most recent relapse.
Change in Income/Cost incurred % Patients
responding ‘Yes’
Affected patients
mean (SD)a
Question respondents
mean (SD)b
Whole sample
mean (SD)c
Reduction in family income –
monthly
31% (28/89) £549.18 (£376.57)
N=22
£145.57 (£309.49)
N=83
£117.30 (£283.46)
N=103
Increase in benefit payments –
monthly
11% (7/65) £303.33 (£254.38)
N=6
£28.44 (£114.35)
N=64
£17.67 (£90.93)
N=103
Additional help and support
required – weekly
15% (10/68) £85.63 (£72.97)
N=8
£10.38 (£36.96)
N=66
£6.65 (£29.93)
N=103
Healthcare Attendance Associated Costs
Parking cost per relapse 33% (25/76) £32.80 (£52.21)
N=22
£9.88 (£32.01)
N=73
£7.00 (£27.27)
N=103
Fuel cost per relapsed 57% (44/77) £37.28 (£62.85)
N=36
£19.45 (£48.84)
N=69
£13.03 (£40.92)
N=103
Public transportcost per relapse 19% (13/67) £24.81 (£32.56)
N=11
£4.20 (£15.92)
N=65
£2.65 (£12.77)
N=103
a
Shows the mean (SD) for all patients who recorded a figure for their financial change.
b
Averages total reported costs over all patients who responded to the question, imputing a £0 cost for those who said ‘no change’.
c
Averages total reported costs over all questionnaire respondents, imputing a £0 cost for anyone who did not record a figure or
answered ‘no’.
d
Where mileage figures were provided a rate of 45p per mile was applied.
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Sixty two percent (40/65) of patients reported more con-
tacts than usual with their GP, 67% (8/12) more contacts
with a “community therapist” (not further specified), 60%
(6/10) more contacts with an occupational therapist, and
54% (7/13) more contacts with a physiotherapist during
their most recent relapse.
Forty one percent (20/50) of patients attended their MS
Specialist Nurse and 35% (19/57) their neurologist more
than usual.
3.2.5. Impact of relapse on attitude to treatment
Of the patients who were taking a DMT at the time of the
most recent relapse, 36% (27/76) reported that they were
more likely to be compliant with DMT treatment following
their most recent relapse and 54% (41/76) reported no
change in compliance.
Before their most recent relapse, 59% (41/70) of respon-
dents who were on a DMT were either ‘very happy’ or
‘happy’ with their treatment. After their most recent
relapse, 57% (43/76) of respondents who were on a DMT,
were either ‘very happy’ or ‘happy’ with their DMT.
3.2.6. Open comments
There were 57 responses to the final question inviting any
other comments the respondent wished to make. The
themes identified in these comments are shown in Table 2.
3.2.6.1. Impact on health and ability. Patients described
physical symptoms and impairments associated with a range
of effects on their abilities, including loss of mobility,
inability to read, write or move independently of carers,
needing to lie down every afternoon and inability to take an
active role in sexual intercourse. One respondent described
their quality of life as ‘reduced to a mere existence’ whilst
another described the impact as ‘nothing that affects myday to day living’. Several people voiced concern at not
regaining their pre-relapse level of health or function.
The psychological impacts mentioned included stress,
fear of the future or the unknown, worry, depression,
feeling alone (despite having a spouse), feeling very emo-
tional, frustration at the limitations imposed by the disease
and, in one case, mental health issues leading to psychiatric
inpatient admission.
M. Duddy et al.4543.2.6.2. Burden on family/friends. This emerged as a
dominant theme, particularly in relation to the spouse/
partner and young children. Specifically the impacts
included the practical – for example, needing family to
take over household chores and cooking. Childcare was also
a big issue with family or friends taking time off work to
accompany/transport them to hospital appointments and
relatives having children to stay during the acute phase of a
relapse. The emotional upset and general ‘burden’ caused
to family was a great concern to some. Some respondents
expressed regret at the change in interaction with family,
including not being able to do what they used to with their
young children/grandchildren. One respondent described
severe strain on their relationship leading to its break up,
which they attributed to MS if not directly to the relapse.
Others acknowledged the importance of the support they
received from their family.
3.2.6.3. Working life. MS relapses were associated with a
range of impacts on respondents' working lives, which in
some cases were clearly described as being of paramount
importance, either for mental health or financial reasons.
People described their MS relapse as causing them to take
time off work, reduce their hours, lose responsibility, retire,
resign or be unable to work since their most recent relapse.
Some respondents described their employers as being
supportive while others described pressure either to return
to work or to resign. Some relied on an intermittent pattern
of work to avoid having to reduce their working hours or
deal with sickness absence sanctions.
3.2.6.4. Finances. Some respondents stressed the impor-
tance of the financial impact, due to their being the
principal earner in the family. Others mentioned factors
that mitigated the financial impact, such as understanding
employers giving family time off work to provide transport
to hospital (which would otherwise have incurred more
cost), and insurance or pensions which provided financial
support when they could no longer work.
3.2.6.5. Health care provision. Several respondents men-
tioned with appreciation the support received from health
care professionals including GPs, MS nurses and doctors.
However some respondents reported difficulties in accessing
appropriate professional help, including delay in obtaining
an appointment, the appointment being too short, poor
communication between GP and hospital and delays in
organising appropriate treatment.
3.2.6.6. Treatment effects. Both positive and negative
responses were included. Some respondents reported a lack
of relapses since starting a DMT, not getting any worse,
milder relapse than prior to starting a DMT and even an
improvement in health;
‘… my [DMT] treatment.. has really given me my quality
of life back’.
Conversely, some respondents focussed on side effects of
treatment, especially where these affected their ability to
work;
'The side effects of [DMT] mean I could not work [the
following day]…which limits work options'
'Having to retire from occupation due to taking DMT'
3.2.6.7. Factors affecting relapse. Some respondents
traced their relapse back to a specific precipitant includinginfections, holidaying in a hot climate, being taken off
medication and pregnancy/childbirth; e.g.
'having my son brought the relapse on'
3.2.6.8. Control. The unpredictability of the disease was
volunteered as having contributed to a feeling of loss of
control and inability to make plans. One respondent
described how they ‘took matters into own hands and
restarted meds’ to regain control.
3.2.6.9. Coping. Various strategies were described. These
ranged from small practical adjustments such as having
shopping delivered and using microwave meals during a
relapse or getting a flu jab to avoid viral illness. The
benefits of a positive outlook were proposed;
'I am very up beat and like to live a normal life and not
let my MS interfere'
Mitigating circumstances identified included being fortu-
nate that they or their spouse had flexible or part time
working patterns or understanding employers.
4. Discussion
As only 27% of all eligible patients took part in the study,
there may be doubts as to the representativeness of this
sample. There was a slightly higher proportion of female
questionnaire respondents than in the eligible population
(77% vs. 71% respectively) but the sex distribution is not
dissimilar to previous population estimates of sex distribu-
tion in RRMS (Alonso et al., 2007). Respondents were
perhaps slightly older and more disabled than might have
been predicted; the mean age at questionnaire completion
(44.9 years) was slightly higher than the mean age of those
eligible (43.5years) on 1st January 2013. Forty-one percent
of respondents had a BDI score of419, indicating moderate
or severe depression, with a median score of 15 (IQR 9 to
23). This is higher than a UK general population BDI mean of
7.25 (Van Hemert et al., 2002) but in line with other
estimates of depression in the UK MS population (Jones
et al., 2012). The quality of life (EQ5D) mean score of 0.60
was lower than the general UK population mean of 0.86 (SD
0.23) (Kind et al., 1999) indicating a worse perceived health
state. EQ5D VAS mean score of 63.0 was also lower than the
UK general population mean score of 85.1 for adults aged
40–49 years (Jones et al., 2012). One might predict an over-
representation of patients who had had a relapse, or been
particularly affected by one, but this direction of bias
cannot be confirmed. The lower response to work related
questions may reflect a genuinely low employment rate,
unclear questioning, or a reluctance to share perceived
sensitive information.
The annualised relapse rate of 0.36 per patient year is
remarkably similar to that seen in clinical trials of beta-
interferon and glatiramer acetate (Roskell et al., 2012). Of
the relapses that were documented, 75% were considered to
be moderate or severe. The generally good patient satisfac-
tion with first line treatment appears unaffected by the
occurrence of relapse. This potentially reflects well-
managed expectations of the limited efficacy of the first
line therapies, which may also be seen in the fact that only
12% of patients stopped all DMTs within 3 years. Eighty
percent of patients were initiated on interferon treatments
455The UK patient experience of relapse in multiple sclerosisand persistence with DMT was good (88% of all patients
remained on a DMT).
The under-reporting of relapses by patients to specialist
clinicians (28% of most recent relapses unreported and 46%
of patients not reporting at least one relapse in the past) is
noteworthy and of concern. In addition to the patient
reported reasons given in this study, infrequent review
schedules, often annual, may contribute to this. As therapy
options expand, alternative methods for better ascertain-
ment of treatment response may need to be considered.
Relapses had a major impact on patients' working lives
with the majority of affected PwMS taking time off sick
and/or reducing their working hours. Permanent, recurring
loss of income through reduction in working hours or with-
drawal from work was seen in 18% of respondents. Perhaps
predictably, since the rest of the survey focussed on this,
impact on working life was also a major theme in the open
comments provided by patients, some of whom were still
the main or only earner in the family. The fear of future
inability to work resulted in a significant mental burden on
some patients.
However, despite the focus of the survey on financial
impact of relapse on patients and their families, the impact
of relapses on family roles and relationships was also a
major theme in respondents' comments. The impacts
described were not only practical but also psychological
and emotional. Many of the open comments focussed on loss
of abilities which could not be quantified in financial terms,
but were clearly significant to respondents, affecting their
quality of life and view of themselves and their role in the
family.
In view of the psychological impact patients reported in
relation to themselves and their families, greater consid-
eration should be given to the provision of psychological as
well as practical or medical support of both patients and
their families at times of disease relapse and to equip them
to deal emotionally with the uncertainty associated with
the course of the disease overall.5. Conclusion
This contemporary UK-based study provides an insight into
the patient experience of relapse early in the treatment
course of RRMS. Until there are validated surrogate markers
of early treatment response, accurate documentation of the
occurrence and impact of relapses is vital to ensure sound
clinical decision-making, and this study reveals some defi-
ciencies in current practice in this regard, associated with
under-reporting by patients. Although cost-effectiveness
studies tend to focus on long term disability, the multi-
factorial impact of individual relapses is highlighted in the
patient responses, emphasising relapse reduction as a
worthy treatment aim in itself.Conflict of interest statement
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